Learning Objectives

By the end of this module, students will be able to:

1. Explain why vascular access selection is a different problem in the older patient starting hemodialysis than in a young, fit starter.
2. Compare the arteriovenous fistula, arteriovenous graft, and tunneled catheter across time-to-use, maturation/failure, infection, patency, and best-fit patient.
3. Describe real-world fistula maturation rates and reintervention burden using the Hemodialysis Fistula Maturation (HFM) Study numbers.
4. Explain how selection bias inflates the observed fistula survival advantage, using the "failed fistula attempt" comparison group.
5. Summarize what the ACCESS-HD pilot trial did and did not establish.
6. Apply the KDOQI ESKD Life-Plan framework and the "right access, right patient, right time, right reason" principle to an access decision.
7. Recognize the high-output cardiac caveat of a fistula in an older patient with a failing heart.

Section 1: Why Access Choice Is Different in the Older Starter

Vascular access is the lifeline of hemodialysis, and it is also one of the largest single drivers of morbidity, hospitalization, and cost in the dialysis population. Three options exist: the autogenous arteriovenous fistula (AVF), the prosthetic arteriovenous graft (AVG), and the tunneled central venous catheter (CVC). For a fit 50-year-old with years of expected survival and good vessels, the fistula is close to unarguable. The calculus bends, sometimes sharply, once the patient is 75, frail, multimorbid, and already dialyzing through a catheter.

Four forces reshape the decision in the older patient:

• Competing mortality. Many older starters die of cardiovascular disease, infection, or dialysis withdrawal long before an access has time to pay back its up-front cost.
• Maturation failure. Fistulas in older patients fail to mature at high rates, and a fistula that never matures leaves the patient on the very catheter you were trying to avoid.
• A short time horizon. The infection and patency advantages of a fistula accrue on the back end. If survival is measured in months, the patient may never reach the payoff.
• Patient preference. Older patients, when actually asked, frequently prefer to keep the catheter they already have.

Clinical Pearl: The question is never "fistula or catheter?" in the abstract. It is "does this patient live long enough, with vessels good enough, to convert the front-loaded cost of a fistula into a back-loaded benefit?" That reframing is the entire topic.

Section 2: The Three Options — Fistula, Graft, and Catheter

A patient-centered decision still requires knowing the honest trade-offs of each access.

Section 3: How "Fistula First" Became Doctrine — and Its Confounding Problem

The fistula's reputation was earned honestly, at first. Early work established that catheters carry the heaviest burden of access-related morbidity — bacteremia, thrombosis, central stenosis, and repeated intervention. Registry and cohort data then layered on a striking survival gap, and guidelines followed.

The most rigorous synthesis is Ravani and colleagues' 2013 systematic review of 62 cohort studies comprising 586,337 participants. The pooled meta-analysis showed the risk gradient ran catheter > graft > fistula across the hard outcomes:

These are large associations, and they drove a generation of practice.

Read the authors' own caveat: Ravani et al. graded the risk of bias in the underlying studies as high, especially selection bias. The association is real; the causal interpretation is where it breaks down.

Section 4: ACCESS-HD — The Trial That Tried to Answer It

Everything above is observational. The obvious fix is a randomized trial, and that is exactly what Quinn, Ravani, and colleagues attempted in ACCESS-HD (Comparing Catheters to Fistulas in Older Patients Starting Hemodialysis), a parallel-arm pilot RCT across 12 centers (9 Canadian, 3 Australian), 2014–2021. Older patients who had started hemodialysis on a catheter and were judged fistula-eligible were randomized 1:1 to a fistula attempt or continued tunneled catheter.

The primary endpoint was feasibility, not a clinical outcome. This is the interpretive key. Two co-primary feasibility targets were set:

Of 268 eligible patients, 201 declined and only 67 were randomized. The most robust, least-biased finding is why patients said no. Among those who declined, 37% preferred to keep their catheter, 23% preferred a fistula, and 17% did not want to join a study. Patient preference — not surgical capacity — was the dominant barrier to running the trial at all.

Section 5: The Patient-Centered Framework — the ESKD Life-Plan

The 2019 KDOQI guideline replaced the rigid Fistula-First slogan with the End-Stage Kidney Disease (ESKD) Life-Plan and the principle of "the right access, in the right patient, at the right time, for the right reasons." That is the framework to actually use.

The decision rests on three questions:

1. What is the expected survival and trajectory? A robust patient with years ahead earns the fistula's back-loaded benefit. A frail patient with a short horizon may never reach it.
2. What are the vessels and the surgical timeline? Poor veins push toward a graft; an urgent need with no mature options may mean a bridging catheter regardless.
3. What does the patient actually want? ACCESS-HD showed this is not a footnote — it is often the deciding factor, and more than a third of eligible older patients preferred their catheter.

Clinical Pearl — the high-output trap in the older heart: Do not forget the cardiac cost of a fistula. In an older patient with reduced ejection fraction or pulmonary hypertension, a high-flow upper-arm fistula can worsen high-output physiology. In that patient the "gold standard" access can be the wrong one on hemodynamic grounds alone — another reason the hierarchy has to yield to the individual.

The honest position: in the robust older patient with good vessels and a long horizon, still favor a fistula — the infection and patency benefits are real if the patient lives to collect them. A graft is a legitimate middle path when veins are poor or the timeline is short. And when a frail older patient who prefers his line says so, ACCESS-HD says you are on solid ground honoring that. Access type matters less than access fit.

Practice Questions

1. A 78-year-old man started hemodialysis on a tunneled catheter three weeks ago. He is frail, has heart failure with reduced ejection fraction, and tells you he would rather keep his catheter. His nephrologist judges him fistula-eligible. What does the best available evidence support?

• 1. Mandatory fistula creation — Fistula First applies to all eligible patients
• 2. Honoring a catheter strategy is reasonable; there is no randomized evidence of harm, and preference is a legitimate deciding factor
• 3. A PICC line as a compromise access
• 4. Immediate graft placement regardless of preference

Correct Answer: B) Honoring a catheter strategy is reasonable ACCESS-HD found no signal of harm from a catheter strategy in older starters, and patient preference was the dominant real-world driver — 37% of decliners preferred their catheter. In a frail patient with heart failure, the high-output physiology of a fistula adds cardiac risk. The decision belongs in the ESKD Life-Plan and shared decision-making, not a rigid hierarchy.

2. In Brown's 2017 cohort, patients who attempted a fistula, had it fail, and started dialysis on a catheter still had lower mortality than patients who started catheter-first. What does this comparison most directly demonstrate?

• 1. Fistulas reduce mortality even when they never mature
• 2. Catheters directly cause most deaths in dialysis patients
• 3. Much of the apparent fistula survival benefit is selection bias — the healthier patient, not the access
• 4. Failed fistula attempts improve vessel health

Correct Answer: C) Much of the apparent fistula survival benefit is selection bias Both groups dialyzed through a catheter, so the survival difference cannot be attributed to the access itself. It reflects whatever made those patients fistula candidates — better health and longer life expectancy. The authors estimated patient factors account for about two-thirds of the apparent benefit. Quinn 2017 reinforced this: only approximately 2% of deaths were access-related.

3. The primary endpoint of the ACCESS-HD trial was:

• 1. All-cause mortality at two years
• 2. Catheter-related bacteremia rate
• 3. Feasibility of conducting the trial (recruitment and timely fistula attempt)
• 4. Access-related procedure count

Correct Answer: C) Feasibility of conducting the trial ACCESS-HD was a pilot trial whose co-primary endpoints were feasibility targets: at least 25% of eligible patients consenting (met, barely, at 25%) and at least 80% of the fistula arm getting an attempt within 90 days (not met, at 71%). The clinical outcomes — mortality, bacteremia, procedures — were underpowered secondary endpoints. The trial's central finding is that a definitive RCT is not feasible, largely because patients prefer their catheters.

Key References

• Ravani P, Palmer SC, Oliver MJ, et al. Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol. 2013;24(3):465–473. PMID: 23431075
• Brown RS, Patibandla BK, Goldfarb-Rumyantzev AS. The Survival Benefit of "Fistula First, Catheter Last" in Hemodialysis Is Primarily Due to Patient Factors. J Am Soc Nephrol. 2017;28(2):645–652. PMID: 27605542
• Quinn RR, Oliver MJ, Devoe D, et al. The Effect of Predialysis Fistula Attempt on Risk of All-Cause and Access-Related Death. J Am Soc Nephrol. 2017;28(2):613–620. PMID: 28143967
• Lyu B, Chan MR, Yevzlin AS, Gardezi A, Astor BC. Arteriovenous Access Type and Risk of Mortality, Hospitalization, and Sepsis Among Elderly Hemodialysis Patients: A Target Trial Emulation Approach. Am J Kidney Dis. 2022;79(1):69–78. PMID: 34118301
• Quinn RR, Ravani P. Fistula-first and catheter-last: fading certainties and growing doubts. Nephrol Dial Transplant. 2014;29(4):727–730. PMID: 24327565
• Huber TS, Berceli SA, Scali ST, et al. Arteriovenous Fistula Maturation, Functional Patency, and Intervention Rates (HFM Study). JAMA Surg. 2021;156(12):1111–1118. PMID: 34550312
• Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1–S164. PMID: 32778223
• Aitken E, Thomson P, Bainbridge L, et al. A randomized controlled trial of early cannulation arteriovenous grafts versus tunneled central venous catheters in patients requiring urgent vascular access for hemodialysis. J Vasc Surg. 2017;65(3):766–774. PMID: 28236919
• Murea M, Gardezi AI, Goldman MP, et al. Study protocol of a randomized controlled trial of fistula vs. graft arteriovenous vascular access in older adults with ESKD on hemodialysis: the AV Access Trial. BMC Nephrol. 2023;24(1). PMID: 36829135
• Quinn RR, Oliver MJ, Wald R, et al. Comparing Catheters to Fistulas in Older Patients Starting Hemodialysis (ACCESS-HD). J Am Soc Nephrol. 2026; Publish Ahead of Print. Note: not yet PubMed-indexed as of July 2026.

Created for PA/Medical Student Education — Last Updated: 2026-07-03. For clinical management decisions, consult current guidelines, institutional protocols, and attending nephrologists.

For the full, reference-verified deep dive, see the mastery review: Vascular Access Selection in Older Patients.